CD276 and bone cancer: Numerous studies have demonstrated that B7-H3 is highly overexpressed in human malignancies and correlates with negative prognosis and poor clinical outcome, including glioma (Wang et al., 2018; Zheng et al., 2019), HCC (Zheng et al., 2019), pancreatic cancer (Inamura et al., 2018), ovarian carcinoma (Zang et al., 2010), colorectal cancer (Ingebrigtsen et al., 2014), and bone cancer (He and Li, 2019).